Hottest Stocks
(Over $10)		 Hottest Stocks
($2-$10)		 Biggest Losers
(Over $10)		 Biggest Losers
($2-$10)		 Hottest
Industries		 Hottest
Sectors		 EPS / Sales
Surprises
 
Enter Ticker Symbol:   Ticker Lookup
 

Enter any portion of the company’s name to find its corresponding ticker symbol:
Search for :   

Zacks Company Profile for Krystal Biotech, Inc. (KRYS : NSDQ)
 
 • Company Description   
Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

Number of Employees: 275

 
 • Price / Volume Information   
Yesterday's Closing Price: $188.33 Daily Weekly Monthly
20 Day Moving Average: 328,957 shares
Shares Outstanding: 28.94 (millions)
Market Capitalization: $5,450.83 (millions)
Beta: 0.64
52 Week High: $207.84
52 Week Low: $122.80
Short Interest Ratio:
  % Price Change % Price Change Relative to S&P 500
4 Week 17.26% 17.31%
12 Week 25.55% 20.52%
Year To Date 20.22% 6.66%
 
 • Address & Contact Information
Street Address Phone / Fax Email Address Web URL
2100 WHARTON STREET SUITE 701
-
PITTSBURGH,PA 15203
USA		 ph: 412-586-5830
fax: -		 investors@krystalbio.com http://www.krystalbio.com
 
 • General Corporate Information   
Officers
Krish S. Krishnan - Chief Executive Officer and President
Suma M. Krishnan - President
Kathryn A. Romano - Chief Accounting Officer
Daniel S. Janney - Director
Dino A. Rossi - Director

Peer Information
Krystal Biotech, Inc. (CORR.)
Krystal Biotech, Inc. (RSPI)
Krystal Biotech, Inc. (CGXP)
Krystal Biotech, Inc. (BGEN)
Krystal Biotech, Inc. (GTBP)
Krystal Biotech, Inc. (RGRX)
Industry / Sector / Ticker Info
Analyst Coverage: No
Industry Group: MED-BIOMED/GENE
Sector: Medical
CUSIP: 501147102
SIC: 2836
Fiscal Year
Fiscal Year End: December
Last Reported Quarter: 06/01/25
Next Expected EPS Date: 11/03/25
Share - Related Items
Shares Outstanding: 28.94
Most Recent Split Date: (:1)
Beta: 0.64
Market Capitalization: $5,450.83 (millions)
 
 
 • EPS Information     • Dividend Information
Analyst Coverage: No Dividend Yield: 0.00%
Current Fiscal Quarter EPS Consensus Estimate: $1.33 Indicated Annual Dividend: $0.00
Current Fiscal Year EPS Consensus Estimate: $4.91 Payout Ratio: 0.00
Number of Estimates in the Fiscal Year Consensus: 6.00 Change In Payout Ratio:
Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00
Next EPS Report Date: 11/03/25  
 

 • Fundamental Ratios
P/E
Current FY Estimate: 38.33
Trailing 12 Months: 38.28
PEG Ratio: -
Price Ratios
Price/Book: 5.24
Price/Cash Flow: 40.61
Price / Sales: 15.17
EPS Growth
vs. Year Ago Period: 50.00%
vs. Previous Quarter: 7.50%
Sales Growth
vs. Year Ago Period: 36.65%
vs. Previous Quarter: 8.91%
ROE
09/30/25 - -
06/30/25 - 15.21
03/31/25 - 14.64
ROA
09/30/25 - -
06/30/25 - 13.81
03/31/25 - 13.28
Current Ratio
09/30/25 - -
06/30/25 - 9.68
03/31/25 - 9.65
Quick Ratio
09/30/25 - -
06/30/25 - 9.33
03/31/25 - 9.27
Operating Margin
09/30/25 - -
06/30/25 - 40.85
03/31/25 - 40.14
Net Margin
09/30/25 - -
06/30/25 - 40.85
03/31/25 - 37.17
Pre-Tax Margin
09/30/25 - -
06/30/25 - 46.98
03/31/25 - 41.39
Book Value
09/30/25 - -
06/30/25 - 35.96
03/31/25 - 34.07
Inventory Turnover
09/30/25 - -
06/30/25 - 0.90
03/31/25 - 1.04
Debt-to-Equity
09/30/25 - -
06/30/25 - 0.00
03/31/25 - 0.00
Debt-to-Capital
09/30/25 - -
06/30/25 - 0.00
03/31/25 - 0.00
 

Powered by Zacks Investment Research ©